62 results
8-K
EX-99.1
STSA
Satsuma Pharmaceuticals Inc
18 May 23
January 2024 PDUFA date expected
4:20pm
.”
Satsuma’s STS101 NDA is supported primarily by clinical trials results from the Phase 1 comparative pharmacokinetic and safety trial of STS101 completed … in June 2021 and the STS101 ASCEND Phase 3 long-term, open-label safety trial in which 446 subjects treated more than 9,000 migraine attacks with more
SC 14D9
STSA
Satsuma Pharmaceuticals Inc
5 May 23
Tender offer solicitation
8:17am
of EMERGE trial results and other data, including preliminary results from the open-label, Phase 3 long-term safety trial of STS101 5.2 mg, or ASCEND … ) the ongoing Phase 3 SUMMIT trial and results to date of the ongoing ASCEND open-label, long-term safety trial, (iv) and engaging a financial advisor
8-K
EX-2.1
STSA
Satsuma Pharmaceuticals Inc
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
contractors, hours of work, leaves of absence, equal opportunity, discrimination, harassment, immigration, occupational health and safety, workers … Labor Relations Board, the U.S. Department of Labor, the U.S. Occupational Health and Safety Administration, the Workers Compensation Appeals Board
SC TO-C
EX-99.1
Shin Nippon Biomedical Laboratories, Ltd.
17 Apr 23
Information about tender offer
6:08am
an easy-to-carry and easy-to-use dosage form, sustained efficacy, and favorable safety and tolerability, we believe that STS101 will contribute to improving
8-K
EX-99.2
zhakmwpbuckt7h
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
8-K
EX-99.1
bjkmkh gv0nbgubaoh
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
8-K
EX-99.1
39642hg 13
30 Nov 22
Other Events
4:00pm
8-K
EX-99.1
rdjyuf 6vtpc
14 Nov 22
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase
4:04pm
8-K
EX-99.2
1d8wrkd
14 Nov 22
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase
4:04pm
424B5
dnoraf6 75slxe
3 Nov 22
Prospectus supplement for primary offering
4:42pm
8-K
EX-99.1
bm5e8
3 Nov 22
Satsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business Highlights
4:00pm
8-K
hc4gk3hl13
20 Sep 22
Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial
5:03pm
8-K
EX-99.1
pet4odzthg2w6
20 Sep 22
Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial
5:03pm
8-K
EX-99.1
jf5o2
10 May 22
Satsuma Pharmaceuticals Reports First Quarter 2022 Financial Results
4:02pm
8-K
EX-99.1
ymvox6up7 jut
15 Mar 22
Satsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business Highlights
4:40pm